{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:39:21Z","timestamp":1790260761238,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pathological N2 (pN2) non-small cell lung cancer (NSCLC) is diverse; its treatment depends on the clinical N (cN) status. We aimed to determine the efficacy of upfront surgery for cN2pN2 NSCLC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The study included 43 cN2pN2 NSCLC patients who underwent upfront surgery at the Shizuoka Cancer Center between 2002 and 2017. Survival outcome, focusing on cN2 status, was retrospectively investigated. Mediastinal lymph nodes were pre-operatively evaluated using computed tomography and positron emission tomography. Surgical eligibility criteria included single-station cN2. N2 with N1 and skip N2 were defined as N2 with and without ipsilateral hilar lymph node metastasis, respectively. A platinum-doublet regimen was used for adjuvant chemotherapy. Survival curves were analysed using the Kaplan\u2013Meier method. Univariate and multivariate analyses were performed using the Cox proportional hazard regression model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Clinical-skip N2 and cN2 with N1 cases included 22 and 21 patients, respectively. Twenty-three patients received adjuvant chemotherapy. The median follow-up duration was 73\u00a0months. Clinical-skip N2 had a significantly better 5-year recurrence-free survival (RFS) than cN2 with N1 (58.3 vs 28.6%, P = 0.038) and was an independent favorable RFS predictor. Recurrence within 18 months occurred in 71% of cN2 with N1 cases. Five-year overall survival and RFS rates in patients receiving adjuvant chemotherapy vs those without adjuvant chemotherapy were 82.2 vs 41.9% (P = 0.019) and 56.5 vs 28.0% (P = 0.049), respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Clinical-skip N2 had an excellent prognosis, and upfront surgery was acceptable. Conversely, upfront surgery followed by chemotherapy is not recommended for cN2 with N1 patients because of early recurrence.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyac209","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T21:45:18Z","timestamp":1673991918000},"page":"429-435","source":"Crossref","is-referenced-by-count":6,"title":["Survival outcome of upfront surgery for clinical single-station N2 non-small cell lung cancer"],"prefix":"10.1093","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7440-8610","authenticated-orcid":false,"given":"Takamitsu","family":"Hayakawa","sequence":"first","affiliation":[{"name":"Division of Thoracic Surgery , Shizuoka Cancer Center Hospital, Shizuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Isaka","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery , Shizuoka Cancer Center Hospital, Shizuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Konno","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery , Shizuoka Cancer Center Hospital, Shizuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery , Shizuoka Cancer Center Hospital, Shizuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kawata","sequence":"additional","affiliation":[{"name":"Division of Pathology , Shizuoka Cancer Center Hospital, Shizuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology , Shizuoka Cancer Center Hospital, Shizuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-2505","authenticated-orcid":false,"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology , Shizuoka Cancer Center Hospital, Shizuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Ohde","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery , Shizuoka Cancer Center Hospital, Shizuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"2023050106131450400_ref1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2023050106131450400_ref2","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(08)70156-6","article-title":"Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer","volume":"9","author":"Thomas","year":"2008","journal-title":"Lancet Oncol"},{"key":"2023050106131450400_ref3","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","article-title":"Induction chemoradiation in stage IIIA\/N2 non-small-cell lung cancer: a phase 3 randomised trial","volume":"386","author":"Pless","year":"2015","journal-title":"Lancet"},{"key":"2023050106131450400_ref4","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1002\/cncr.26689","article-title":"A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903)","volume":"118","author":"Katakami","year":"2012","journal-title":"Cancer"},{"key":"2023050106131450400_ref5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"key":"2023050106131450400_ref6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0003-4975(10)64717-0","article-title":"The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis","volume":"46","author":"Naruke","year":"1988","journal-title":"Ann Thorac Surg"},{"key":"2023050106131450400_ref7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0022-5223(99)70153-4","article-title":"The prognosis of surgically resected N2 non-small cell lung cancer: the importance of clinical N status","volume":"118","author":"Suzuki","year":"1999","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2023050106131450400_ref8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0169-5002(01)00207-0","article-title":"Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan clinical oncology group to plan for clinical trials","volume":"34","author":"Ichinose","year":"2001","journal-title":"Lung Cancer"},{"key":"2023050106131450400_ref9","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/JTO.0b013e31824c945b","article-title":"Surgical outcome of stage IIIA- cN2\/pN2 non-small-cell lung cancer patients in Japanese lung cancer registry study in 2004","volume":"7","author":"Yoshino","year":"2012","journal-title":"J Thorac Oncol"},{"key":"2023050106131450400_ref10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jjco\/hyt164","article-title":"Surgical outcomes after initial surgery for clinical single-station N2 non-small-cell lung cancer","volume":"44","author":"Hishida","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"2023050106131450400_ref11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa031644","article-title":"Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer","volume":"350","author":"Arriagada","year":"2004","journal-title":"N Engl J Med"},{"key":"2023050106131450400_ref12","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1056\/NEJMoa043623","article-title":"Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer","volume":"352","author":"Winton","year":"2005","journal-title":"N Engl J Med"},{"key":"2023050106131450400_ref13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(06)70804-X","article-title":"Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB\u2013IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial","volume":"7","author":"Douillard","year":"2006","journal-title":"Lancet Oncol"},{"key":"2023050106131450400_ref14","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023050106131450400_ref15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00595-015-1268-2","article-title":"Outcomes of initial surgery in patients with clinical N2 non-small cell lung cancer who met 4 specific criteria","volume":"46","author":"Maniwa","year":"2016","journal-title":"Surg Today"},{"key":"2023050106131450400_ref16","doi-asserted-by":"crossref","first-page":"6828","DOI":"10.21037\/jtd.2018.10.115","article-title":"Upfront surgery in patients with clinical skip N2 lung cancer based on results of modern radiological examinations","volume":"10","author":"Maniwa","year":"2018","journal-title":"J Thorac Dis"},{"key":"2023050106131450400_ref17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/ejcts\/ezaa042","article-title":"Long-term outcomes of upfront surgery in patients with resectable pathological N2 non-small-cell lung cancer","volume":"58","author":"Yun","year":"2020","journal-title":"Eur J Cardiothorac Surg"},{"key":"2023050106131450400_ref18","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jtcvs.2017.10.075","article-title":"Upfront surgery as first-line therapy in selected patients with stage IIIA non-small cell lung cancer","volume":"155","author":"Zheng","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2023050106131450400_ref19","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"2023050106131450400_ref20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1200\/JCO.20.01820","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial","volume":"39","author":"Zhong","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023050106131450400_ref21","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"2023050106131450400_ref22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","article-title":"The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours","volume":"2","author":"Goldstraw","year":"2007","journal-title":"J Thorac Oncol"},{"key":"2023050106131450400_ref23","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/ejcts\/ezt195","article-title":"Recurrence of mediastinal node cancer after lobe-specific systematic nodal dissection for non-small-cell lung cancer","volume":"44","author":"Maniwa","year":"2013","journal-title":"Eur J Cardiothorac Surg"},{"key":"2023050106131450400_ref24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.resinv.2012.09.002","article-title":"Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: a retrospective study in Japan","volume":"50","author":"Kenmotsu","year":"2012","journal-title":"Respir Investig"},{"key":"2023050106131450400_ref25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00280-017-3400-z","article-title":"Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer","volume":"80","author":"Kenmotsu","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2023050106131450400_ref26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (lung ART): an open-label, randomised, phase 3 trial","volume":"23","author":"Le Pechoux","year":"2022","journal-title":"Lancet Oncol"},{"key":"2023050106131450400_ref27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2023050106131450400_ref28","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/JTO.0000000000000678","article-title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer","volume":"10","author":"Asamura","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2023050106131450400_ref29","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/ejcts\/ezu028","article-title":"Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer","volume":"45","author":"De Leyn","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"2023050106131450400_ref30","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023050106131450400_ref31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/JTO.0b013e3181c814e7","article-title":"Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the lung adjuvant cisplatin evaluation","volume":"5","author":"Douillard","year":"2010","journal-title":"J Thorac Oncol"},{"key":"2023050106131450400_ref32","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"2023050106131450400_ref33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.lungcan.2017.11.014","article-title":"Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: implications for adjuvant therapy","volume":"115","author":"Isaka","year":"2018","journal-title":"Lung Cancer"},{"key":"2023050106131450400_ref34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jjco\/hyz188","article-title":"Radiotherapy for local recurrence of non-small-cell lung cancer after lobectomy and lymph node dissection-can local recurrence be radically cured by radiation?","volume":"50","author":"Terada","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"2023050106131450400_ref35","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ijrobp.2008.01.044","article-title":"Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the Adjuvant Navelbine International Trialist Association (ANITA) randomized trial","volume":"72","author":"Douillard","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023050106131450400_ref36","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.radonc.2013.10.008","article-title":"Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with IIIA-pN2 non-small cell lung cancer: an early closed randomized controlled trial","volume":"110","author":"Shen","year":"2014","journal-title":"Radiother Oncol"},{"key":"2023050106131450400_ref37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3816\/CLC.2007.n.005","article-title":"A phase III study of surgical resection and paclitaxel\/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: cancer and leukemia group B 9734","volume":"8","author":"Perry","year":"2007","journal-title":"Clin Lung Cancer"},{"key":"2023050106131450400_ref38","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.jtho.2017.09.1954","article-title":"Randomized phase II trial comparing chemoradiotherapy with chemotherapy for completely resected unsuspected N2-positive non-small cell lung cancer","volume":"12","author":"Sun","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2023050106131450400_ref39","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaoncol.2021.1910","article-title":"Effect of postoperative radiotherapy for patients with pIIIA-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy: the phase 3 PORT-C randomized clinical trial","volume":"7","author":"Hui","year":"2021","journal-title":"JAMA Oncol"},{"key":"2023050106131450400_ref40","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","article-title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients\u2019 data","volume":"14","author":"Mauguen","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/5\/429\/50138042\/hyac209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/5\/429\/50138042\/hyac209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T06:13:41Z","timestamp":1682921621000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/53\/5\/429\/6991225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,1,18]]},"published-print":{"date-parts":[[2023,4,29]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyac209","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2023,1,18]]}}}